Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0.1275
Stock impact report

ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

ASLAN Pharmaceuticals Ltd ADS (ASLN)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF - ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study - 3 patients completed 1 month of dosing and achieved average reduction in EASI score of 71%. Maximal efficacy expected at 6 to 8 weeks. SINGAPORE, Dec. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose (MAD) study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN004 is a first-in-class fully human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signalling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of AD, such as redness and itching of the skin. The first patient was enrolled into the double blind study at Changi General Hospital in Singapore on 22 October 2019. [Read more]
Impact snapshot Event time: ASLN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ASLN alerts
from News Quantified
Opt-in for
ASLN alerts

from News Quantified
Opt-in for
ASLN alerts

from News Quantified